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ABSTRACT 
Background and Objectives: Triple anti-platelet therapy may produce more potent inhibition of platelet aggre-
gation in patients undergoing coronary stent implantation. We tested whether this effect could be maintained in 
diabetic patients, where platelet reactivity is increased and the risk of stent thrombosis is higher. Subjects and 
Methods: Fifty five type 2 diabetic patients who had undergone drug-eluting stent (DES) implantation and chronic 
anti-platelet therapy (>1 month) were stratified according to the status of anti-platelet therapy. Platelet aggregation 
after adenosine diphosphate (ADP; 10 μmol/L and 20 μmol/L) stimulation was compared using light transmittance 
aggregometry between dual (aspirin plus clopidogrel, n=34) and triple therapy (aspirin, clopidogrel plus cilostazol, 
n=21) groups. Results: The 2 groups had similar clinical and procedural characteristics. Maximal ADP-induced 
platelet aggregation was significantly lower in the triple therapy group than the dual therapy group (ADP 10 μmol/L, 
37.1±15.4 vs. 28.3±11.8, p=0.03; ADP 20 μmol/L, 63.1±15.0 vs. 49.1±15.1, p=0.01), but there were no 
differences in diabetic treatment (oral hypoglycemic agent vs. insulin) or diabetic control {hemoglobin Alc (HbA1c) 
≤7 vs. HbA1c >7}. Conclusion: Triple anti-platelet therapy showed more potent inhibition of maximal ADP in-
duced platelet aggregation in type 2 diabetic patients receiving chronic anti-platelet therapy. This finding suggests 
that triple antiplatelet therapy may be more effective in preventing thrombotic complications after DES implanta-
tion in type 2 diabetic patients. (Korean Circ J 2009;39:462-466) 
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Introduction 
 
Type 2 diabetic patients have approximately 2 to 4-
fold higher incidence of coronary artery diseases than 
non-diabetic patients, and restenosis commonly occurs 
after coronary stent implantation.
1)2) Type 2 diabetes 
mellitus is also a risk factor for stent thrombosis after 
the implantation of drug-eluting stents (DES).
3) Func-
tional changes in platelets can increase cardiovascular 
complications in type 2 diabetic patients
4-6) and decrease 
the response to aspirin,
7)8) which increases the risk of de-
veloping coronary artery disease.
9-11) Platelet aggregation 
is higher in diabetic patients after a loading-dose of clo-
pidogrel, and platelet aggregation and activity are also 
higher after the administration of aspirin and clopidogrel 
for more than 1 month.
12) Thus, the anti-platelet effects 
of clopidogrel and aspirin are decreased in diabetic pa-
tients. The triple anti-platelet therapy with aspirin, clo-
pidogrel, and cilostazol is more effective in preventing 
stent thrombosis than dual anti-platelet therapy with 
aspirin, clopidogrel, or ticlopidine.
13) Triple therapy also 
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inhibits platelet aggregation and activity more than dual 
therapy after the drug-induced stimulation of platelets.
14)  
To date, however, there is no data comparing dual and 
triple therapy in type 2 diabetic patients. Therefore, we 
tested platelet aggregation after double and triple therapy 
using optical aggregometry in type 2 diabetic patients that 
received anti-platelet drugs after DES implantation.   
  
Subjects and Methods 
 
Subjects 
We recruited 55 patients with type 2 diabetes mellitus 
who had received a DES at least one month earlier that 
then visited the outpatient clinic between March and 
May, 2008. Patients were taking anti-platelet agents 
without any notable clinical events. Patients were divided 
into a dual therapy group, with aspirin and clopidogrel, 
or a triple therapy group, with aspirin, clopidogrel, and 
cilostazol. The selection of anti-platelet agents was whol-
ly based on physician discretion. Exclusion criteria were: 
patients with impaired glucose tolerance not taking oral 
hypoglycemic agents, patients taking oral anti-coagula-
tion agents, patients taking non-steroidal anti-inflam-
matory agents before the platelet aggregation test, pa-
tients who abused other drugs or alcohol, patients whose 
platelet counts were less than 100,000/ μL, patients 
whose hematocrit was less than 25%, patients whose se-
rum creatinine was higher than 2.5 mg/dL, and patients 
whose serum liver enzymes were 2 times higher than 
normal. An institutional review committee approved 
this study and all subjects gave informed consent.   
 
Platelet aggregation test 
The brachial vein was directly punctured with a 22-
gauge needle and blood was drawn. The first 2- to 3 mL 
blood to avoid the spontaneous activation of platelets. 
The remaining blood was placed in a test tube contain-
ing 3.8% trisodium citrate. Within an hour following 
blood sampling, the degree of maximal platelet aggrega-
tion was measured using optical aggregometry (Chro-
nolog Aggregometer, Norbis, Stuttgart, Germany) after 
platelet stimulation with adenosine diphosphate (ADP), 
10 μmol/L and 20  μmol/L. Centrifugation was per-
formed at 800 r.p.m. for 10 minutes, and supernatant 
was harvested to prepare platelet-rich plasma. Using au-
tologous plasma, platelet counts were set at 250,000/μL. 
Platelet-poor plasma was generated by a secondary cen-
trifugation at 2,500 r.p.m. for 10 minutes. The light trans-
mittance of platelet-rich plasma was set at 0% and that 
of platelet-poor plasma was set at 100%. The curve of 
blood coagulation was recorded for six minutes at each 
measurement. The degree of platelet aggregation was ex-
pressed as the percent changes in the light transmittance 
of platelet-rich plasma at 37℃ following ADP stimula-
tion based on platelet-poor plasma (100%). At each meas-
urement, the maximal platelet aggregation was measured. 
 
Statistical analysis 
Continuous variables were expressed as mean±stand-
ard deviation and categorical variables are expressed as 
the frequency and its percentage. Continuous variables 
following a normal distribution were analyzed using Stu-
dent’s t-test, non-normal data were analyzed using Mann-
Whitney test. Categorical variables were analyzed using 
the Chi-square test or Fisher’s exact test. A value of p< 
0.05 was considered statistically significant. All the statis-
tical analyses were performed using Statistical Package for 
Social Science (SPSS) 15.0 (SPSS Inc. Chicago, IL, USA). 
Table 1. Clinical characteristics of patients (n=55) 
  Double group (n=34)  Triple group (n=21)  p
Age (years)  63.8±8.2 63.4±7.6 0.93
Men, n (%)  21 (60.0)  12 (40.0)  0.78
Risk factors, n (%)       
Hypertension  20 (57.1)  13 (61.9)  0.79
Hypercholesterolemia 14  (41.2)  06 (28.6)  0.40
Current smoking  07 (20.6)  03 (14.3)  0.73
Duration of diabetes (year)  04.6±3.1  05.0±2.8 0.69
Hemoglobin A1C (%)  7.6  7.1  0.34
Insulin dependent, n (%)  06 (18.2)  05 (23.8)  0.73
Medical treatment, n (%)       
Beta blockers  22 (64.7)  14 (66.7)  1.00
Calcium blockers  12 (35.3)  06 (28.6)  0.77
Nitrates 19  (55.9)  08 (38.1)  0.27
ACE inhibitors or ARB  30 (88.2)  19 (90.5)  1.00
Statins  33 (97.1)  21 (100). 1.00
Platelet count, 10
3/ μL  254.7±71.6 238.1±57.2 0.37
Ccr (mL/min)  057.1±14.6 53.9±9.6 0.36
ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker, Ccr: creatinine clearance calculated by Cockcroft and Gault method  
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Results 
 
Clinical characteristics   
We enrolled 34 patients receiving dual therapy and 
21 patients receiving triple therapy. All patients were 
taking 100 mg aspirin and 75 mg clopidogrel a day. Pa-
tients on triple therapy also took 200 mg cilostazol a day. 
There were no differences in the duration of diabetes 
mellitus, cardiovascular risk factors, creatinine clearance 
as calculated using the methods of Cockcroft and Gault, 
treatment agents other than anti-platelet agents, or he-
matologic tests (Table 1). In the dual therapy group, 30 
patients were treated with 39 sirolimus-eluting stents (S-
ES) and 4 patients were treated with 6 paclitaxel-eluting 
stents (PES). In the triple therapy group, 18 patients were 
treated with 22 SESs and 3 patients were treated with 
4 PESs. Anti-platelet agents had been administered af-
ter DES implantation for 224.2±93.2 days in the dual 
therapy group and 181.2±121.2 days in the triple ther-
apy group (p=0.18).  
 
Platelet aggregation test 
Platelet aggregation was lower in the triple therapy 
group than the dual therapy group after 10  μmol/L A-
DP (28.3±11.8% vs. 37.1±15.4%, p=0.03) and 20 
μmol/L ADP (49.1±15.1% vs. 63.1±15.0%, p=0.01) 
(Fig. 1). Maximum platelet aggregation was not different 
in the insulin or oral hypoglycemic groups (Table 2). 
Maximum platelet aggregation was not different based 
on diabetic control status, as measured by hemoglobin 
levels of A1c 7.0 (Table 3).  
 
Discussion 
 
We found that triple therapy with aspirin, clopidogrel, 
and cilostazol inhibited ADP-induced platelet aggrega-
tion better than dual therapy with aspirin and clopido-
grel in type 2 diabetic patients after DES implantation. 
Similarly, Lee et al.
14) found that triple therapy inhibited 
platelet aggregation better than dual therapy after DES 
implantation, although that study included non-diabetic 
and diabetic patients.   
Type 2 diabetes mellitus is equivalent to coronary ar-
tery disease and presents higher thrombogenic potential 
that increases cardiovascular risk. Vascular endothelial 
dysfunction, abnormal fibrinolysis, increased levels of 
coagulation factors, alterations of platelet function, and 
the decreased response to anti-platelet agents are closely 
associated with the formation of blood clots.
4-8) Platelet 
responses to aspirin can be decreased even though 
thromboxane A2 in diabetics, but clopidogrel can also 
help prevent cardiovascular diseases in type 2 diabetic 
patients.
15) Dual therapy with aspirin and clopidogreal 
would be more effective than individual treatments, but 
is less effective in type 2 diabetic patients.
12) 
Cilostazol and clopidogrel suppress ADP-induced pla-
telet aggregation, but they work differently. Clopidogrel 
blocks the ADP receptor to inhibit adenylate cyclase, 
whereas cilostazol suppresses phosphodiesterase III acti-
vity. Both drugs therefore elevate the intracellular con-
centration of cyclic adenosine monophosphate (cAM-
P),
16)17) which suppresses platelet aggregation better than 
either drug alone. Clinical studies have demonstrated 
that the triple therapy could lower the incidence of stent 
Table 3. Maximal platelet aggregation following 20  μM/L ADP according to diabetic control
  HbA1c ≤7 (n=30)  HbA1c >7 (n=25)  p
Platelet aggregation, n (%)       
Double group*  17 (63.5±14.2) 17  (62.7±16.1) 0.90
Triple group
† 13  (47.4±14.4)  08 (52.0±16.4) 0.16
All patients  56.5±16.3 59.3±16.7 0.42
*Double: aspirin plus clopidogrel,  †Triple: aspirin, clopidogrel plus cilostazol. ADP: adenosine diphosphate, HbA1c: hemoglobin A1c 
Table 2. Maximal platelet aggregation following 20  μM/L ADP according to hypoglycemic therapy modalities 
  Insulin (n=11)  OHA (n=44)  p
Platelet aggregation, n (%)       
Double group*  06 (65.0±11.7) 28  (62.7±15.8) 0.90
Triple group
†  05 (57.2±6.9) 0 16  (46.6±16.2) 0.16
All patients  11 (61.5±10.2) 44  (56.9±17.6) 0.54
*Double: aspirin plus clopidogrel,  †Triple: aspirin, clopidogrel plus cilostazol. ADP: adenosine diphosphate, OHA: oral hypoglycemic agents
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Fig. 1. Maximal platelet aggregation following ADP (10 and 20 μM)
in type 2 diabetic patients according to anti-platelet drugs (Double,
aspirin plus clopidogrel; Triple, aspirin, clopidogrel plus cilostazol).
Numbers in the box denote the mean value of platelet aggregation.
ADP: adenosine diphosphate. 
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thrombosis more than dual therapy.
13)18)  
Enhanced platelet activation may be a consequence 
of more prevalent atherosclerotic lesions or reflect the 
influence of metabolic disturbances on platelet biochem-
istry and function. Decreased responses to anti-platelet 
agents may result from increased ADP receptors on the 
platelet surface, oxidative stress resulting in aspirin-
insensitive thromboxane biosynthesis, and altered struc-
ture of the platelet membrane and enhanced protein 
glycation reducing interaction with drug target.
19)20) Be-
cause protein glycation can decrease the efficacy of anti-
platelet agents, diabetic treatment modalities, either hy-
poglycemic agents or insulin, or diabetic control, may 
influence anti-platelet activity. However, we did not find 
differences in treatment modalities or diabetic status in 
either therapy group. However, the small number of pa-
tients on insulin and the large number of patients with 
good diabetic control limit the strength of this conclu-
sion. The degree of platelet aggregation was somewhat 
higher in patients with insulin treatment or hemoglo-
bin A1c (HbA1c) of >7.0, suggesting that triple therapy 
would be effective for these patients. 
Greater suppression of platelet aggregation in triple 
therapy might increase the incidence of complications 
including hemorrhage, and could increase medication 
expenses. Large-scale clinical studies did not show dif-
ferences for the two therapies in the incidence of com-
plications such as bleeding or gastrointestinal complica-
tions.
13)21)22) The lack of established criteria for treatment 
periods for anti-platelet agents implies the need for indi-
vidual treatment plans. The results of this study suggests 
that triple therapy may be useful in type 2 diabetic pa-
tients with left main coronary artery lesion, bifurcation 
lesions, or long lesions with high risk of stent thrombosis. 
DES can also produce later stent thrombosis than bare-
metal stents, indicating that triple therapy may be indi-
cated long after stent implantation. Cilostazol can also 
reduce restenosis,
21) which has significant clinical benefit. 
There are some limitations of the current study. First, 
we used a retrospective analysis of medical records based 
on a single-center experience in a small number of pa-
tients, which could have selection bias. Second, we en-
rolled patients in an outpatient clinic without major car-
diac events after DES implantation. Third, there were 
some discrepancies in the period of the use of anti-pla-
telet agents. These limitations prevent the results of the 
current study from being generalized. Further prospec-
tive, randomized studies that are currently planned at 
our institution in patients with type 2 diabetes mellitus 
could overcome these limitations. Finally, we used opti-
cal aggregometry and did not measure clinical outcomes 
of inhibiting platelet aggregation. Further large-scale cli-
nical studies are warranted to clarify differences in dual 
and triple therapy in diabetic patients. 
In conclusion, triple therapy inhibited platelet aggre-
gation more than dual therapy in type 2 diabetic patients 
taking anti-platelet agents. The current study provides an 
experimental basis for the selective use of triple therapy 
in patients with stents at high risk for thrombosis. 
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